19/11/2024 06:30
EQS-News: Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: 9 Month figures/Conference br/ Formycon invites to earnings call on the ninemonth results 2024 and announces participation in international investor... Lire...
18/11/2024 06:30
EQS-News: Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Statement/Regulatory Admission br/ Formycon receives positive CHMP opinion for FYB203 aflibercept, a biosimilar candidate to Eylea® under the tradenames... Lire...
15/11/2024 18:18
EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Formycon AG / Key words: Statement/Regulatory Admissionbr/ AfliberceptBiosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA br/br/ 15Nov2024 / 18:18... Lire...
11/11/2024 17:41
EQS-News: Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Personnel/Contract br/ Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime... Lire...
04/11/2024 06:30
EQS-News: Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Regulatory Admission/IPO br/ Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange br/br/ 04.11.2024 / 06:30... Lire...
16/10/2024 06:50
EQS-News: Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Scientific publication/Study results br/ Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in... Lire...
01/10/2024 17:06
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
html xmlns=http://www.w3.org/1999/xhtmlbodytable border=trtd p OriginalResearch: Formycon AG from First Berlin Equity Research GmbH br/br/ 01.10.2024 / 17:05 CET/CESTbr/ Dissemination of a Research, transmitted by EQS News a service of EQS Group AG.br/ The issuer is solely responsible... Lire...
30/09/2024 07:30
EQS-News: Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Regulatory Approval/Market Launch br/ Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM ustekinumabaauz br/br/ 30.09.2024 /... Lire...
27/09/2024 21:56
EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Formycon AG / Key words: Regulatory Approvalbr/ FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM ustekinumabaauz br/br/ 27Sep2024 / 21:56 CET/CESTbr/ Disclosure of an inside information... Lire...